Edwards Lifesciences Corp. (NYSE: EW) reported Q3 EPS of $0.38, $0.01 worse than the analyst estimate of $0.39. Revenue for the quarter came in at $412.7 million versus the consensus estimate of $405.09 million.

Earnings